ReWalk Robotics Showcases AI in Exoskeleton Prototype

28 November 2023 | Tuesday | News

R&D Grant from the Israeli Technology Innovation Consortium Enabled the Successful Demonstration of a Working Prototype
Image Source | Public Domain

Image Source | Public Domain

ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced the successful demonstration of a proof-of-concept next-generation exoskeleton. As part of the Israel Innovation Authority’s MAGNET incentive program, the Human Robot Interaction Consortium (the “HRI Consortium”), the company has reached a milestone by integrating advanced sensing technologies and artificial intelligence (“AI”) to enable autonomous decision making in the Company’s latest exoskeleton prototype.

“We have successfully demonstrated that by combining advanced sensor technology and artificial intelligence, the ReWalk Exoskeleton can detect and react to changes in terrain, leading to a potentially new generation of smart exoskeletons,” said David Hexner, Vice President of Research & Development at ReWalk. “We continue to advance our design objectives for the next generation of exoskeletons by making them easier and safer to use, reducing the cognitive load on the user, and broadening the use case to more activities of everyday life.”

“With today’s announcement, ReWalk continues its tradition of innovation in the design and practical use of exoskeletons for individuals living with spinal cord injury,” said Larry Jasinski, CEO of ReWalk. “As our recent success with Medicare continues to broaden coverage for exoskeletons, ReWalk is committed to making exoskeletons more accessible and easier to use with each generation. We are excited to fully incorporate these advancements into future ReWalk exoskeletons.”

The MAGNET incentive program provides R&D and collaboration grants to private businesses and leading academic centers. The goals of the HRI Consortium are to “develop advanced technologies aimed at providing robots with social capabilities, enabling them to carry out various tasks and effective interactions with different users in diverse operational environments.” The Consortium seeks to develop a Human-Robot Interaction Toolkit for Robot Operating Systems which could potentially yield income to contributing members.

As a member of the HRI Consortium, ReWalk collaborates with several universities to develop advanced technologies aimed at improving the human-exoskeleton interaction. With top researchers in the fields of robotics, behavioral sciences, and human-computer interaction, this research seeks to widen adoption by making the use of exoskeletons easier, more natural and more broadly accepted. The Consortium is a three-year project which started in May 2022. ReWalk is one of nine companies participating in the HRI Consortium, in addition to several Israeli universities.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close